SEC Form 4 · accession 0001214659-18-007631
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — EVP, Chief Scientific Officer
Period of report
Dec 6, 2018
Accepted (ET)
Dec 10, 2018 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 3,620 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Grant (Right to Buy)F2 | $39.76 | Dec 6, 2018 | A | 30,000 | A | — | Dec 5, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Includes 226 shares acquired under the ESPP Purchase on 11/30/18.
- F21/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.